07:00 , Oct 18, 2010 |  BioCentury  |  Politics, Policy & Law

Vaccine Pandora's box

If the U.S. Supreme Court sides with the petitioners in Bruesewitz v. Wyeth , the rulingcould undermine the National Childhood Vaccine Injury Act of 1986 and drag the field back decades to a time when...
07:00 , Aug 20, 2007 |  BioCentury  |  Regulation

Watchdog rebuffed on Gardasil

The not-for-profit National Vaccine Information Center called for a warning about Gardasil based on an analysis released last week suggesting the HPV vaccine is associated with an increased risk of serious adverse events when given...
07:00 , Jun 13, 2005 |  BC Week In Review  |  Clinical News

Adacel regulatory update

FDA approved a BLA for Adacel tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed for adolescents and adults aged 11-64 years. The vaccine was unanimously recommended for approval by an FDA advisory committee...
08:00 , Mar 21, 2005 |  BC Week In Review  |  Clinical News

Adacel regulatory update

FDA's Vaccines and Related Biological Products Advisory Committee unanimously recommended approval of Adacel tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed for adolescents and adults aged 11-64 years. sanofi-aventis Group (Euronext:SAN; SNY), Paris,...
08:00 , Jan 31, 2000 |  BC Week In Review  |  Clinical News

North American Vaccine preclinical data

NVX reported that in mice the combination of its Hib and acellular pertussis vaccines produced no significant immunologic interferences. NVX plans to market the Hib vaccine, which is in preclinical development, in combination with its...
08:00 , Nov 1, 1999 |  BC Week In Review  |  Clinical News

Haemophilus influenzae type b (Hib) conjugate vaccine: Began Phase I testing

North American Vaccine Inc. (NVX), Columbia, Md.   Product: Haemophilus influenzae type b (Hib) conjugate vaccine   Business: Infectious diseases   Therapeutic category: Viral infection   Target: Immune cells   Description: Conjugate vaccine coupled with...
07:00 , May 3, 1999 |  BC Week In Review  |  Clinical News

North American Vaccine regulatory update

Austria granted marketing approval for NVX's DTaP, a combined diphtheria, tetanus and acellular pertussis vaccine, and its DTaP-IPV injectable polio virus vaccine. Chiron Behring GmbH & Co. (Marburg, Germany) will distribute the products in Austria...
08:00 , Feb 8, 1999 |  BioCentury  |  Strategy

Chiron rationalizes vaccines

Sometimes having a potentially approvable product doesn't pay. That is the decision Chiron Corp. made last week in tailoring its vaccines program to exploit its strengths and not waste resources on marketing efforts that are...
08:00 , Mar 23, 1998 |  BC Week In Review  |  Clinical News

Chiron, Evans Medical Ltd. regulatory update

CHIR said that the European Patent Office revoked Evans's Patent No. 0 162 639 covering the pertactin antigen of Bordetella pertussis, which is used in CHIR's acellular pertussis vaccine. SmithKline Beecham Biologicals S.A. (Rixensart, Belgium)...
08:00 , Jan 19, 1998 |  BC Week In Review  |  Company News

Chiron, Evans Medical Ltd. infectious diseases news

The U.K.'s High Court of Justice ruled that the U.K. portion of Evans Medical's European Patent No. 162,639 is invalid. Evans Medical, a subsidiary of Medeva Group PLC (London, U.K.), had asserted that the '639...